CN101780078B - 替米沙坦和氨氯地平复方制剂及其制备方法 - Google Patents
替米沙坦和氨氯地平复方制剂及其制备方法 Download PDFInfo
- Publication number
- CN101780078B CN101780078B CN2010101081968A CN201010108196A CN101780078B CN 101780078 B CN101780078 B CN 101780078B CN 2010101081968 A CN2010101081968 A CN 2010101081968A CN 201010108196 A CN201010108196 A CN 201010108196A CN 101780078 B CN101780078 B CN 101780078B
- Authority
- CN
- China
- Prior art keywords
- micropill
- parts
- amlodipine
- telmisartan
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 150000001875 compounds Chemical class 0.000 title claims abstract description 23
- 229940043097 telmisartan and amlodipine Drugs 0.000 title claims abstract description 15
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims abstract description 54
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims abstract description 27
- 229960005187 telmisartan Drugs 0.000 claims abstract description 27
- 229960000528 amlodipine Drugs 0.000 claims abstract description 17
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 29
- 239000003085 diluting agent Substances 0.000 claims description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000007779 soft material Substances 0.000 claims description 17
- 229960004005 amlodipine besylate Drugs 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 229920002472 Starch Polymers 0.000 claims description 13
- 239000008107 starch Substances 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- 239000000080 wetting agent Substances 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- -1 amlodipine besylate compound Chemical class 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 7
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 7
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 6
- 229960003194 meglumine Drugs 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 5
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 150000008044 alkali metal hydroxides Chemical group 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 4
- 229940077388 benzenesulfonate Drugs 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000006187 pill Substances 0.000 abstract 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 20
- 206010020772 Hypertension Diseases 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 229940079593 drug Drugs 0.000 description 9
- 230000001476 alcoholic effect Effects 0.000 description 6
- 238000005422 blasting Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- RSGAIWOEJXRYRV-UHFFFAOYSA-M sodium;2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoate Chemical compound [Na+].CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C([O-])=O RSGAIWOEJXRYRV-UHFFFAOYSA-M 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000010008 shearing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000010247 heart contraction Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- VCOYRKXQRUGBKS-UHFFFAOYSA-N N.[Cl] Chemical compound N.[Cl] VCOYRKXQRUGBKS-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101081968A CN101780078B (zh) | 2010-02-10 | 2010-02-10 | 替米沙坦和氨氯地平复方制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101081968A CN101780078B (zh) | 2010-02-10 | 2010-02-10 | 替米沙坦和氨氯地平复方制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101780078A CN101780078A (zh) | 2010-07-21 |
CN101780078B true CN101780078B (zh) | 2012-02-29 |
Family
ID=42520306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101081968A Active CN101780078B (zh) | 2010-02-10 | 2010-02-10 | 替米沙坦和氨氯地平复方制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101780078B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102327264B (zh) * | 2011-07-20 | 2013-08-14 | 海南锦瑞制药股份有限公司 | 一种氨氯地平与替米沙坦药用组合物及制备方法 |
CN203123076U (zh) * | 2012-03-12 | 2013-08-14 | 成都自豪药业有限公司 | 替米沙坦氨氯地平片 |
CN106389431A (zh) * | 2016-11-06 | 2017-02-15 | 成都先先先生物科技有限公司 | 一种治疗原发性高血压的药物复方制剂 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008095263A1 (en) * | 2007-02-09 | 2008-08-14 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
-
2010
- 2010-02-10 CN CN2010101081968A patent/CN101780078B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008095263A1 (en) * | 2007-02-09 | 2008-08-14 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
Also Published As
Publication number | Publication date |
---|---|
CN101780078A (zh) | 2010-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2777696B1 (en) | Preparation of stable pharmaceutical dosage forms | |
JP2003231634A (ja) | バルサルタンの固体経口剤形 | |
KR100525341B1 (ko) | 고형 발사르탄 약제학적 조성물 | |
KR20100063090A (ko) | 알리스키렌 및 발사르탄의 생약 제제 | |
CA2858478C (en) | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing | |
CN101851247B (zh) | 含有硫酸氢氯吡格雷晶体颗粒的组合物 | |
EP3661508A1 (en) | Manufacturing method of oral dosage form containing berberine, oral dosage form containing berberine and use thereof | |
CN101780078B (zh) | 替米沙坦和氨氯地平复方制剂及其制备方法 | |
CN109875972B (zh) | 一种奥美沙坦酯氨氯地平药物组合物 | |
AU2003237807A1 (en) | Sustained release of guaifenesin combination drugs | |
CN101711751A (zh) | 非布索坦分散片及其制备方法 | |
JP2020114834A (ja) | セリチニブ製剤 | |
CA2312512C (en) | Directly compressible starch as enhancer of properties of excipients when used as binder and disintegrant for compression tablets | |
Mbah et al. | Effect of process parameters on the properties of some metronidazole tablet and capsule formulations | |
CN104771377A (zh) | 一种含有西他列汀或其药用盐的口服速释制剂的制备方法 | |
CN106619547A (zh) | 一种低规格美洛昔康片剂组合物及其制备方法 | |
JPH08310969A (ja) | 固形薬品組成物及びその製造方法 | |
KR20110063684A (ko) | 알리스키렌을 포함하는 생약 제형 및 용융 압출 과립화에 의한 그의 제조 방법 | |
CN108272763A (zh) | 一种羟苯磺酸钙分散片及其制备方法 | |
CN108066304A (zh) | 具有缓释性能的坦索罗辛口腔崩解片组合物 | |
US20130217774A1 (en) | Novel process for preparing dexibuprofen ready to compress granules | |
CN106913550B (zh) | 一种醋酸艾司利卡西平片的制备方法 | |
CN101732269A (zh) | 一种含有单硝酸异山梨酯的分散片 | |
CN104884048B (zh) | 高含量布洛芬钠颗粒、其制备及其在制备非泡腾固体剂型中的用途 | |
CN102342967A (zh) | 维参锌薄膜包衣片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 410300 No. 97 Kangping Road, Liuyang Economic and Technological Development Zone, Changsha City, Hunan Province Patentee after: Hunan Weite Pharmaceutical Co.,Ltd. Address before: 410331 No. 2 Wei2 Road, Liuyang Biomedical Park, Changsha City, Hunan Province Patentee before: WEIGHTECH (HUNAN) PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compound preparation of telmisartan and amlodipine and preparation method thereof Effective date of registration: 20200416 Granted publication date: 20120229 Pledgee: Liuyang Rural Commercial Bank Co.,Ltd. of Hunan Province through its branch Pledgor: Hunan Weite Pharmaceutical Co.,Ltd. Registration number: Y2020430000005 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230505 Granted publication date: 20120229 Pledgee: Liuyang Rural Commercial Bank Co.,Ltd. of Hunan Province through its branch Pledgor: Hunan Weite Pharmaceutical Co.,Ltd. Registration number: Y2020430000005 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compound preparation of telmisartan and amlodipine and its preparation method Effective date of registration: 20230522 Granted publication date: 20120229 Pledgee: Liuyang Rural Commercial Bank Co.,Ltd. of Hunan Province through its branch Pledgor: Hunan Weite Pharmaceutical Co.,Ltd. Registration number: Y2023980041217 |